First Wave BioPharma Analyst Ratings
First Wave BioPharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/19/2023 | 2727.76% | Roth MKM | → $11 | Reiterates | Buy → Buy |
| 07/14/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 06/29/2023 | 2470.69% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 06/13/2023 | 2470.69% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 05/15/2023 | 2470.69% | HC Wainwright & Co. | $14 → $10 | Reiterates | Buy → Buy |
| 04/26/2023 | 3498.97% | HC Wainwright & Co. | → $14 | Reiterates | → Buy |
| 04/05/2023 | 3498.97% | HC Wainwright & Co. | $18 → $14 | Maintains | Buy |
| 03/09/2023 | 4527.25% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 02/03/2023 | 4527.25% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 01/31/2023 | 4527.25% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 01/26/2023 | 4527.25% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 12/02/2022 | 928.28% | HC Wainwright & Co. | $8 → $4 | Maintains | Buy |
| 05/26/2022 | 2213.62% | Roth Capital | $20 → $9 | Maintains | Buy |
| 12/07/2021 | — | Maxim Group | Downgrades | Buy → Hold |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/19/2023 | 2727.76% | Roth MKM | → 11 美元 | 重申 | 購買 → 購買 |
| 07/14/2023 | — | HC Wainwright & Co. | 降級 | 買入 → 中性 | |
| 06/29/2023 | 2470.69% | HC Wainwright & Co. | → 10 美元 | 重申 | 購買 → 購買 |
| 06/13/2023 | 2470.69% | HC Wainwright & Co. | → 10 美元 | 重申 | 購買 → 購買 |
| 05/15/2023 | 2470.69% | HC Wainwright & Co. | 14 美元 → 10 美元 | 重申 | 購買 → 購買 |
| 2023 年 4 月 26 日 | 3498.97% | HC Wainwright & Co. | → 14 美元 | 重申 | → 購買 |
| 04/05/2023 | 3498.97% | HC Wainwright & Co. | 18 美元 → 14 美元 | 維護 | 購買 |
| 03/09/2023 | 4527.25% | HC Wainwright & Co. | → 18 美元 | 重申 | → 購買 |
| 02/03/2023 | 4527.25% | HC Wainwright & Co. | → 18 美元 | 重申 | → 購買 |
| 01/31/2023 | 4527.25% | HC Wainwright & Co. | → 18 美元 | 重申 | → 購買 |
| 01/26/2023 | 4527.25% | HC Wainwright & Co. | → 18 美元 | 重申 | → 購買 |
| 12/02/2022 | 928.28% | HC Wainwright & Co. | 8 美元 → 4 美元 | 維護 | 購買 |
| 2022 年 5 月 26 日 | 2213.62% | 羅斯資本 | 20 美元 → 9 美元 | 維護 | 購買 |
| 2021 年 7 月 12 日 | — | Maxim 集團 | 降級 | 買入 → 持有 |
What is the target price for First Wave BioPharma (FWBI)?
First Wave BioPharma（FWBI）的目標價格是多少？
The latest price target for First Wave BioPharma (NASDAQ: FWBI) was reported by Roth MKM on September 19, 2023. The analyst firm set a price target for $11.00 expecting FWBI to rise to within 12 months (a possible 2727.76% upside). 12 analyst firms have reported ratings in the last year.
Roth MKM於2023年9月19日公佈了First Wave BioPharma（納斯達克股票代碼：FWBI）的最新目標股價。該分析公司將目標股價定爲11.00美元，預計FWBI將在12個月內升至12個月內（可能上漲2727.76％）。去年有12家分析公司公佈了評級。
What is the most recent analyst rating for First Wave BioPharma (FWBI)?
First Wave BioPharma（FWBI）的最新分析師評級是多少？
The latest analyst rating for First Wave BioPharma (NASDAQ: FWBI) was provided by Roth MKM, and First Wave BioPharma reiterated their buy rating.
First Wave BioPharma（納斯達克股票代碼：FWBI）的最新分析師評級由Roth MKM提供，First Wave BioPharma重申了買入評級。
When is the next analyst rating going to be posted or updated for First Wave BioPharma (FWBI)?
First Wave BioPharma（FWBI）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of First Wave BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for First Wave BioPharma was filed on September 19, 2023 so you should expect the next rating to be made available sometime around September 19, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與First Wave BioPharma的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。First Wave BioPharma的最新評級是在2023年9月19日提交的，因此你應該預計下一個評級將在2024年9月19日左右公佈。
Is the Analyst Rating First Wave BioPharma (FWBI) correct?
分析師對First Wave BioPharma（FWBI）的評級正確嗎？
While ratings are subjective and will change, the latest First Wave BioPharma (FWBI) rating was a reiterated with a price target of $0.00 to $11.00. The current price First Wave BioPharma (FWBI) is trading at is $0.39, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的First Wave BioPharma（FWBI）評級，目標股價爲0.00美元至11.00美元。First Wave BioPharma（FWBI）目前的交易價格爲0.39美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。